News

Article

EMA Validates MAA for Leo Pharma’s Tralokinumab

Leo Pharma, medical dermatology specialist, has announced that the European Medicines Agency (EMA) has validated its marketing authorization application (MAA) for tralokinumab.

Leo Pharma, medical dermatology specialist, has announced, in a June 11, 2020 press release, that the European Medicines Agency (EMA) has validated its marketing authorization application (MAA) for tralokinumab.

Tralokinumab is an investigational, fully human, immunoglobin G4 monoclonal antibody for the treatment of adult patients with moderate-to-severe atopic dermatitis (AD). EMA’s decision to validate the MAA for tralokinumab has been based on data from ECZTRA 1,2, and 3 Phase III studies, which evaluated the efficacy and safety of the treatment as monotherapy.

“People living with atopic dermatitis often face tremendous physical, social, and emotional challenges,” said Kim Kjøller, executive vice-president, Global Research and Development, LEO Pharma, in the press release. “Since atopic dermatitis is a heterogeneous disease, we are focused on targeted therapies with the potential to treat individual needs and reduce this burden. We look forward to working closely with EMA as they review this application.”

Source: Leo Pharma

 

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
Related Content